Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06375954 | EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) | not yet recruiting | N/A | 96 | Hospital Universitari de BellvitgeOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06373133 | SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 36 | West China HospitalOTHER | 0 | Apr 18, 2024 | clinicaltrials |
| NCT06369441 | Collection of Biological Specimens and Associated Health Information | not yet recruiting | — | 10,000 | Ovation.io, Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | not yet recruiting | — | 260 | Peking University People's HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT) | not yet recruiting | Phase 1 / Phase 2 | 117 | Fudan UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06366945 | Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC | not yet recruiting | Phase 2 | 85 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06368934 | Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | not yet recruiting | N/A | 326 | Huashan HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06360978 | Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | not yet recruiting | N/A | 225 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06355921 | A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors(RFAdesmoid) | not yet recruiting | N/A | 27 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT05621824 | A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS | not yet recruiting | — | 900 | Peking Union Medical College HospitalOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06200233 | Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor | not yet recruiting | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06355518 | Pre-operative Immuno-Nutrition in Radical Cystectomy(INu-RC) | not yet recruiting | N/A | 260 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06349967 | Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer | not yet recruiting | Phase 2 | 59 | West China HospitalOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06346808 | Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06347458 | BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children | not yet recruiting | Phase 1 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT06343116 | Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer(NOTABLE-308) | not yet recruiting | Phase 3 | 420 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT05773079 | Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 28 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06315270 | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | not yet recruiting | — | 100 | The First Hospital of Jilin UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06339216 | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06336954 | Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Mar 29, 2024 | clinicaltrials |
| NCT06334913 | A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms | not yet recruiting | — | 1,000 | Guy's and St Thomas' NHS Foundation TrustOTHER | 0 | Mar 28, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335576 | Establishment of Serum Proteomics Subtypes of Gastric Cancer and Its Clinical Application | not yet recruiting | — | 89 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 28, 2024 | clinicaltrials |
| NCT06332950 | Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Baohui HanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06333509 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | not yet recruiting | Phase 1 / Phase 2 | 166 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06325423 | Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06329323 | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours(SUMMER) | not yet recruiting | — | 24 | Imperial College LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06329648 | Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer(DECIDE) | not yet recruiting | — | 20,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331260 | Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 600 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331273 | Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 800 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331845 | Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | not yet recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 0 | Mar 25, 2024 | clinicaltrials |
| NCT06318884 | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 76 | Sinocelltech Ltd.INDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | not yet recruiting | Phase 2 | 10 | Dalian Medical UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06323148 | Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) | not yet recruiting | Phase 3 | 226 | Fudan UniversityOTHER | 0 | Mar 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2024source: clinicaltrials